Xinhua Pharmaceutical announced that it recently received the “Drug Registration Certificate” for valsartan capsules approved and issued by the State Drug Administration. The drug specification is 80 mg. It is a prescription drug and class 4 chemicals. It is used to treat mild and moderate primary hypertension. It is a medical insurance category A. In September 2024, the company submitted the listing license application materials and was accepted, and approved in December 2025. In 2024, sales of valsartan capsules in public medical institutions in China were about 1.82 billion yuan. Approval is beneficial to enrich the company's cardiovascular disease product line and enhance competitiveness, but drug sales are affected by policy, market and other factors, and there is uncertainty.

Xinhua Pharmaceutical announced that it recently received the “Drug Registration Certificate” for valsartan capsules approved and issued by the State Drug Administration. The drug specification is 80 mg. It is a prescription drug and class 4 chemicals. It is used to treat mild and moderate primary hypertension. It is a medical insurance category A. In September 2024, the company submitted the listing license application materials and was accepted, and approved in December 2025. In 2024, sales of valsartan capsules in public medical institutions in China were about 1.82 billion yuan. Approval is beneficial to enrich the company's cardiovascular disease product line and enhance competitiveness, but drug sales are affected by policy, market and other factors, and there is uncertainty.